WHO ICTRP trial
A multiple dosing study to demonstrate the safety, tolerability…
NL-OMON51226 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON51226 |
|---|---|
| Public title | A multiple dosing study to demonstrate the safety, tolerability, pharmacokinetics and efficacy potential of intravenously administered ANXV (a recombinant human Annexin A5) in patients with confirmed moderate to severe COVID-19; The CO-ANNEXIN Study. |
| Scientific title | A multiple dosing study to demonstrate the safety, tolerability, pharmacokinetics and efficacy potential of intravenously administered ANXV (a recombinant human Annexin A5) in patients with confirmed moderate to severe COVID-19; The CO-ANNEXIN Study. - The CO-ANNEXIN STUDY |
| Primary sponsor | Medisch Universitair Ziekenhuis Maastricht |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | The Netherlands |
| Conditions | COVID-19 pneumonia; SARS-COV-2 infection;10003816;10047438;10037454;COVID-19 pneumonia; SARS-COV-2 infection |
| Interventions | The first 6 consecutive patients will receive 1 mg ANXV i.v. in 60 minutes, (t=0) and 1 mg ANXVV i.v. in 15 minutes (t=8h), on day 1. The next day these 6 patients, in case there have been no safety issues, will receive 2 mg ANXV i.v. in 60… |
| Registration date | Dec 13, 2021 |
| Target size | 12 |
| Secondary IDs | 2021-002200-12;NL77746.068.21;nog niet bekend |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: